Physician profile
Genesis Cabrera
NPI 1255063343
$8,261.75
in general payments reported to CMS, 2019-2025
20 companies · $2,792 in 2025
The $2,792 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,690 · 2024: $1,779 · 2025: $2,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,330 · Consulting Fee: $750 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,329.77 |
| Consulting Fee | $750.00 |
| Education | $181.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,471.23 | 2023-2025 | |
| Genzyme Corporation | $1,431.54 | 2023-2025 | |
| Lilly USA, LLC | $1,086.07 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Genentech USA, INC. | $750.00 | 2023 | Xolair |
| Janssen Biotech, INC. | $740.12 | 2023-2025 | Tremfya, Stelara |
| Arcutis Biotherapeutics, INC. | $441.08 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $357.12 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $350.76 | 2023-2025 | Adbry, Anzupgo |
| Incyte Corporation | $261.04 | 2023-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $259.03 | 2023 | Dupixent, Libtayo |
| Pfizer INC. | $229.24 | 2024-2025 | |
| Ucb, INC. | $202.30 | 2023-2025 | Cimzia, Bimzelx |
| Galderma Laboratories, L.P. | $195.33 | 2024-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $171.18 | 2023-2025 | Ilumya |
| Sanofi-Aventis U.S. LLC | $86.99 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.78 | 2023-2024 | Siliq, Cabtreo |
| Dermavant Sciences, INC. | $61.41 | 2023-2024 | Vtama |
| Biofrontera INC. | $46.41 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $21.96 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.16 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Genesis Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.